Emris Pharma, a recent spin-off of Hadasit Medical Research Services and Development Ltd. and Yissum Research Development Co., has started development of a new topical drug to treat skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitors used to treat cancer.
Researchers from Stanford University have published an article on the discovery of novel analogues of ponatinib that retained antitumor efficacy with substantially reduced cardiotoxicity.
LONDON – It was third time lucky for Acacia Pharma Group plc, as the FDA finally gave approval to Barhemsys (amisulpride) as a rescue treatment for surgical patients suffering postoperative nausea and vomiting (PONV), despite standard-of-care treatment.
What with the lawsuits, declining prescriptions and approval hurdles that seem to be the U.S. answer to a nationwide opioid epidemic, drug companies have to think long and hard before spending the resources to develop yet another opioid drug. And patients are paying the price.
A reference genome from the Indian cobra compiled in an international collaborative study should lead to the development of new safer and more effective antivenoms, while the elucidated genome and predicted associated proteome may be a powerful platform for studies of venomous snakes.
A reference genome from the Indian cobra compiled in an international collaborative study should lead to the development of new safer and more effective antivenoms, while the elucidated genome and predicted associated proteome may be a powerful platform for studies of venomous snakes.
Preclinical animal and cellular models are notoriously bad at predicting drug candidate toxicity in humans. Animal biology is often fundamentally different on this front than in humans, while cells in the lab can't be counted on routinely to replicate the bodily response.
RSS
